Cingulate Inc. (NASDAQ: CING), which is a biopharmaceutical firm that concentrates on developing innovative treatments for Attention Deficit/Hyperactivity Disorder (ADHD), has had an exceptional day.
Investors cheered the European patent that the company secured on CTx-1301, its main asset in the treatment of ADHD.
Stocks are rising sharply, as this patent represents a major milestone for the global expansion of the company. The stock of Cingulate is on course to end this week at a gain totaling more than 400%.
What is the significance of European Patents for CING
Cingulate’s newly acquired patent will change the game for it, as its portfolio of intellectual property is now extended beyond the United States and includes up to thirty European countries including the United Kingdom.
This development allows CING to expand their footprint on these markets, and become a major player in the global ADHD market.
The neurodevelopmental disease affects millions of people worldwide. This patent comes at a good time, given the increased recognition that ADHD is a serious health issue in Europe.
This news comes just days after the biopharmaceutical firm announced that it has $0.4 million of cash and equivalents in order to cover its operations until the third quarter 2024.
Cingulate may disrupt the ADHD market
Cingulate has now decided to file an NDA with the US Food & Drug Administration. Shane J. Schaffer, its CEO said this in a Friday press release:
As we continue to demonstrate the clinical success with CTx-1301, we look forward to receiving additional patents.
CING’s dual-pronged strategy, which involves seeking US approval while simultaneously securing a patent in Europe, shows the company’s well-coordinated and ambitious global strategy.
CTx-1301 may improve quality of life and patient compliance, as the drug is only administered once daily, unlike other ADHD medications that are given in multiple doses throughout the day. This can lead to inconsistent symptoms management, and even issues with compliance, particularly among children and teenagers.
Cingulate has seen a dramatic increase in its stock value, reflecting investor confidence about the company’s ability to revolutionize the ADHD market. According to Grand View Research, the global ADHD market is expected to grow to $24.9 billion in 2025. Cingulate’s patent expansion and innovative products will allow it to take a large share of that market.
Cingulate shares surge 115% following European Patent approval of ADHD treatment. Is this a good buy? The ICD first published the article Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?
This site is for entertainment only. Click here to read more
